C
Chenguang Shen
Researcher at Southern University of Science and Technology
Publications - 38
Citations - 6047
Chenguang Shen is an academic researcher from Southern University of Science and Technology. The author has contributed to research in topics: Virus & Antibody. The author has an hindex of 15, co-authored 33 publications receiving 4640 citations. Previous affiliations of Chenguang Shen include Xiamen University & Chinese Academy of Sciences.
Papers
More filters
Journal ArticleDOI
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Chenguang Shen,Zhaoqin Wang,Fang Zhao,Yang Yang,Jinxiu Li,Jing Yuan,Fuxiang Wang,Delin Li,Delin Li,Minghui Yang,Li Xing,Jinli Wei,Haixia Xiao,Haixia Xiao,Yan Yang,Jiuxin Qu,Ling Qing,Li Chen,Zhixiang Xu,Ling Peng,Yanjie Li,Haixia Zheng,Feng Chen,Kun Huang,Yujing Jiang,Dongjing Liu,Zheng Zhang,Yingxia Liu,Lei Liu +28 more
TL;DR: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status, and these observations require evaluation in clinical trials.
Journal ArticleDOI
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.
Qingxian Cai,Minghui Yang,Dongjing Liu,Jun Chen,Dan Shu,Junxia Xia,Xuejiao Liao,Yuanbo Gu,Qiu’e Cai,Yang Yang,Chenguang Shen,Xiaohe Li,Ling Peng,Deliang Huang,Jing Zhang,Shurong Zhang,Fuxiang Wang,Jiaye Liu,Li Chen,Shuyan Chen,Zhaoqin Wang,Zheng Zhang,Ruiyuan Cao,Wu Zhong,Yingxia Liu,Lei Liu +25 more
TL;DR: In this open-label nonrandomized control study, FPV showed significantly better treatment effects on COVID-19 in terms of disease progression and viral clearance; if causal, these results should be important information for establishing standard treatment guidelines to combat the SARS-CoV-2 infection.
Journal ArticleDOI
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.
Yan Wu,Yan Wu,Feiran Wang,Feiran Wang,Chenguang Shen,Weiyu Peng,Weiyu Peng,Delin Li,Cheng Zhao,Zhaohui Li,Shihua Li,Yuhai Bi,Yang Yang,Yuhuan Gong,Haixia Xiao,Zheng Fan,Shuguang Tan,Guizhen Wu,Wenjie Tan,Xuancheng Lu,Changfa Fan,Qihui Wang,Yingxia Liu,Chen Zhang,Jianxun Qi,George F. Gao,Feng Gao,Lei Liu +27 more
TL;DR: In isolation of four human-origin monoclonal antibodies from a convalescent patient, all of which display neutralization abilities, a therapeutic study in a mouse model validated that these antibodies can reduce virus titers in infected lungs.
Posted ContentDOI
Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections
Yang Yang,Minghui Yang,Chenguang Shen,Fuxiang Wang,Jing Yuan,Jinxiu Li,Mingxia Zhang,Zhaoqin Wang,Li Xing,Jinli Wei,Ling Peng,Gary Wong,Haixia Zheng,Weibo Wu,Mingfeng Liao,Kai Feng,Jianming Li,Qianting Yang,Juanjuan Zhao,Zheng Zhang,Lei Liu,Yingxia Liu +21 more
TL;DR: Sputum is most accurate for laboratory diagnosis of NCP, followed by nasal swabs, followedby nasal swab, and detection of viral RNAs in BLAF is necessary for diagnosis and monitoring of viruses in severe cases.
Journal ArticleDOI
Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19.
Yang Yang,Chenguang Shen,Jinxiu Li,Jing Yuan,Jinli Wei,Fengmin Huang,Fuxiang Wang,Guobao Li,Yanjie Li,Li Xing,Ling Peng,Minghui Yang,Mengli Cao,Haixia Zheng,Weibo Wu,Rongrong Zou,Delin Li,Zhixiang Xu,Haiyan Wang,Mingxia Zhang,Zheng Zhang,George F. Gao,Chengyu Jiang,Lei Liu,Yingxia Liu +24 more
TL;DR: These findings add to the understanding of the immunopathologic mechanisms of SARS-CoV-2 infection, and provide potential therapeutic targets and strategies.